How Much Does Legal Psilocybin-Assisted Therapy Cost in Australia, and Is It Covered by Medicare or Private Health Insurance?
Legal psilocybin-assisted therapy (PAT) in Australia represents a groundbreaking advance in mental health treatment. Nevertheless, access comes with a significant financial cost. The price of a full course of PAT is substantial, and while Medicare does not currently cover it, private health insurance is beginning to step in. Consequently, understanding these costs and the evolving coverage landscape is essential for patients considering this innovative therapy.
How Much Does Psilocybin Therapy Cost?
The cost of a standard course of psilocybin-assisted therapy in Australia is reported to be between $20,000 and $30,000 AUD . This estimate covers the entire treatment package, which includes:
- The psilocybin medicine: The cost of the pharmaceutical-grade psilocybin.
- The psychotherapy sessions: This is the most significant cost, as PAT is a people-intensive therapy . It includes multiple preparation sessions before dosing, the dosing session itself (which requires at least two therapists for approximately six hours), and several integration sessions afterward .
Specific Costs Reported:
- At the Empax Centre in Perth, psilocybin therapy costs about $20,000 .
- For MDMA therapy (for PTSD), the cost at the same clinic is about $30,000 . The intensity of the MDMA program, which often involves three dosing sessions, explains the higher cost .
- In general, out-of-pocket expenses for patients seeking this alternative treatment for PTSD and TRD can reach up to $30,000 .
These high costs are the primary barrier to access for most Australians, with the intense one-on-one therapy and the requirement for an Authorised Prescriber psychiatrist to be on-site during the entire session being the main cost drivers .
Is Psilocybin Therapy Covered by Medicare?
No, psilocybin-assisted therapy is not currently covered by Medicare.
The TGA’s decision to allow psychiatrists to prescribe psilocybin was based on safety and effectiveness, but it did not include a cost-effectiveness assessment . A public subsidy, such as a listing on the Pharmaceutical Benefits Scheme (PBS), requires a separate approval process.
For a medicine to be subsidised on the PBS, the Pharmaceutical Benefits Advisory Committee (PBAC) must approve it. A detailed submission is required, demonstrating the medicine’s cost-effectiveness compared to existing treatments. To date, no such submission for psilocybin has been made, and it is not listed on the PBS .
Is Psilocybin Therapy Covered by Private Health Insurance?
Yes, but coverage is currently limited to specific programs and clinics.
Private health insurance is beginning to play a role in making PAT more affordable. This is a significant development, as it could establish a sustainable reimbursement pathway for these therapies .
Medibank’s Initiative:
Medibank, Australia’s largest private health insurer, has committed $50 million over five years to improve mental health access . This includes a dedicated $10 million program to fund psychedelic-assisted psychotherapy pilots . The program initially covered MDMA-assisted therapy for PTSD in Perth . It has since expanded to cover psilocybin-assisted therapy for treatment-resistant depression at specific clinics .
This means eligible Medibank customers with a diagnosed condition who attend a participating clinic, such as Avive Health in Brisbane or the Empax Centre in Perth, can have the therapy fully rebated, saving tens of thousands of dollars .
Conclusion
Legal psilocybin-assisted therapy in Australia is effective, with a strong safety record, but it remains expensive . The standard treatment costs between $20,000 and $30,000, making it financially out of reach for most Australians. Currently, Medicare does not cover these treatments. Nevertheless, private health insurers like Medibank are piloting coverage programs at select clinics, offering a potential path to affordability. Access is also limited by the small number of Authorised Prescribers . As the system matures and more data is collected, coverage is likely to expand. This guide is for educational and research purposes only and does not constitute legal advice.